Bristol-Myers Squibb stock closes near weekly low amid persistent short-term pressure

Traders Union
All News
Companies
Bristol-Myers Squibb drops 1.09% today

Highlights

BMY trades below key short- and medium-term moving averages, indicating continued downside pressure despite long-term support.
Momentum indicators show persistent bearish sentiment and weak trend strength, though the stock appears mildly oversold.
The expected range for BMY is $54.95–$55.71 next week, with a high probability of further declines barring a breakout above immediate resistance.

Short-term downside and long-term support as moving averages diverge

BMY is currently trading at $55.87, positioned below both the MA-20 ($56.97) and MA-50 ($57.90), but above the long-term MA-200 ($53.29). This setup reflects continued short- and medium-term downside pressure, while the long-term trend remains supported. The Ichimoku Kijun on D1 sits at $57.19, acting as immediate resistance above the price. For near-term support, watch the MA-200 ($53.29), with further key support at the MA-100 ($58.33). Immediate resistance is found at the Kijun ($57.19), followed by key resistance at the MA-50 ($57.90).

Bearish momentum and lack of trend as sellers dominate intraday action

Momentum indicators on D1 show bearish momentum, with both MACD and ADX signaling weakness and little trend strength. RSI (47.54) and CCI (-58.85) suggest a mildly oversold setup, while Stoch RSI signals potential for a near-term rebound but no strong reversal yet. BBP indicates sellers currently dominate intraday action. In today’s session, BMY is down 1.09%, reflecting notable pressure. Over the past week, the stock has fallen $1.40, or 2.44%, trading at $55.87 versus a previous week close of $57.27. Price is in the lower part of the weekly range, while weekly volatility stands at 4.60%. The week reflects a steady decline from recent highs.

Further downside favored as upside probabilities remain limited

Looking ahead, the expected trading range for BMY over the next week is $54.95 to $55.71, positioning the stock just above its 52-week low and well below the year’s high. Using W1 indicators, the probability of a price increase is very low (less than 20%), making a further decline the more likely scenario. The baseline expectation is for price to consolidate within the $54.95–$55.71 corridor. A bullish move requires a break above $57.19 resistance, which could open a short-term recovery toward the upper band. Conversely, a bearish scenario would see the price fall below $53.29 support, bringing yearly lows into focus.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Bristol-Myers Squibb was consolidating after signs of medium- and long-term bullish momentum, with analysts highlighting a critical resistance level to monitor for a potential trend shift. In light of the latest developments, investors should closely watch for renewed price direction as the company’s clinical updates continue to influence market sentiment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.